- Emicizumab prophylaxis was safe and reduced bleeds in pediatric patients with hemophilia A and Inhibitors (PwHAwI).
Why this matters
- Emicizumab may reduce the treatment/disease burden for pediatric PwHAwI.
- HAVEN 2 is a single-arm, multicenter, op...
You’ve reached the visitor articles limit
reserved for healthcare professionals
Register to read more
Already have an account? Login now